Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2016 | The price of new innovation for the treatment of multiple myeloma

Eric Low • 12 Apr 2016
COMy 2016
Multiple Myeloma

Eric Low, Chief Executive of Myeloma UK, discusses recent advances in the development of new drugs for the treatment of patients with multiple myeloma and emphasises the importance of determining the cost effectiveness of new therapeutic approaches to ensure patient access.
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

More from Eric Low

Why global collaborations are key in multiple myeloma 2:50
Why global collaborations are key in multiple myeloma
Eric Low • 28 Apr 2016
Improving strategies for executing successful clinical trials in multiple myeloma 3:28
Improving strategies for executing successful clinical trials in multiple myeloma
Eric Low • 8 Jun 2016
Myeloma UK as a driver of collaboration between industry and academia 1:41
Myeloma UK as a driver of collaboration between industry and academia
Eric Low • 7 Oct 2016
The rationale behind the Myeloma UK Clinical Trial Network 3:05
The rationale behind the Myeloma UK Clinical Trial Network
Eric Low • 7 Oct 2016

Related Videos

The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma 4:45
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Ola Landgren • 6 Dec 2025
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry 1:29
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry
Karthik Ramasamy • 7 Dec 2025
The hottest myeloma abstracts from ASH 2025: in vivo CAR-T and MajesTEC-3 2:33
The hottest myeloma abstracts from ASH 2025: in vivo CAR-T and MajesTEC-3
Faith Davies • 7 Dec 2025
Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL 2:30
Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL
James Berenson • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals